AnaptysBio, Inc.ANABNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
232.61%
↑ 514% above average
Average (39q)
-56.15%
Historical baseline
Range
High:307.46%
Low:-1168.86%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 232.61% |
| Q2 2025 | 4.97% |
| Q1 2025 | -184.79% |
| Q4 2024 | 57.51% |
| Q3 2024 | 43.56% |
| Q2 2024 | 4.45% |
| Q1 2024 | -0.16% |
| Q4 2023 | -11.67% |
| Q3 2023 | 6.01% |
| Q2 2023 | 9.59% |
| Q1 2023 | -70.95% |
| Q4 2022 | 12.35% |
| Q3 2022 | -6.60% |
| Q2 2022 | 12.44% |
| Q1 2022 | -1.90% |
| Q4 2021 | -360.70% |
| Q3 2021 | -1168.86% |
| Q2 2021 | 97.10% |
| Q1 2021 | -155.06% |
| Q4 2020 | 237.02% |
| Q3 2020 | -7.51% |
| Q2 2020 | -120.76% |
| Q1 2020 | 53.94% |
| Q4 2019 | 34.04% |
| Q3 2019 | -26.12% |
| Q2 2019 | -8.01% |
| Q1 2019 | -25.98% |
| Q4 2018 | -16.44% |
| Q3 2018 | -17.15% |
| Q2 2018 | 8.52% |
| Q1 2018 | -120.35% |
| Q4 2017 | 21.31% |
| Q3 2017 | -255.66% |
| Q2 2017 | 74.42% |
| Q1 2017 | -214.68% |
| Q4 2016 | -195.26% |
| Q3 2016 | -145.49% |
| Q2 2016 | 307.46% |
| Q1 2016 | 68.29% |
| Q4 2015 | -417.58% |